Efficacy of pertussis components in an acellular vaccine, as assessed in a murine model of respiratory infection and a murine intracerebral challenge model

Vaccine. 2002 Jan 31;20(9-10):1429-34. doi: 10.1016/s0264-410x(01)00460-1.

Abstract

The efficacy of 10 pertussis vaccines prepared from various concentrations of pertussis toxin (PT) and filamentous hemagglutinin (FHA) was investigated in a murine model of respiratory infection (aerosol challenge model) and a murine intracerebral (ic) challenge model. PT was necessary as a vaccine component for protection against an ic challenge with Bordetella pertussis. FHA appeared to play an important role as a vaccine component in protection against an aerosol challenge with B. pertussis. Vaccines containing a small amount of FHA with a large amount of PT (FHA:PT=1:11 or 2:10, w/w) were strongly protective in both the aerosol challenge and the ic challenge models. Ratios of FHA:PT of 1:11 or 2:10 (w/w) might be suitable for future formulations.

MeSH terms

  • Adhesins, Bacterial / administration & dosage*
  • Adhesins, Bacterial / immunology
  • Aerosols
  • Animals
  • Brain / microbiology*
  • Disease Models, Animal*
  • Dose-Response Relationship, Immunologic
  • Female
  • Hemagglutinins / administration & dosage*
  • Hemagglutinins / immunology
  • Lung / microbiology*
  • Mice
  • Pertussis Toxin*
  • Pertussis Vaccine / administration & dosage*
  • Pertussis Vaccine / immunology
  • Time Factors
  • Vaccines, Acellular / administration & dosage
  • Virulence Factors, Bordetella / administration & dosage*
  • Virulence Factors, Bordetella / immunology

Substances

  • Adhesins, Bacterial
  • Aerosols
  • Hemagglutinins
  • Pertussis Vaccine
  • Vaccines, Acellular
  • Virulence Factors, Bordetella
  • filamentous hemagglutinin adhesin, Bordetella pertussis
  • Pertussis Toxin